<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4961">
  <stage>Registered</stage>
  <submitdate>28/01/2015</submitdate>
  <approvaldate>28/01/2015</approvaldate>
  <nctid>NCT02352753</nctid>
  <trial_identification>
    <studytitle>Multicenter,Single-arm Study to Evaluate Efficacy, Safety, &amp; Pharmacokinetics of Denosumab in Children w/ OI</studytitle>
    <scientifictitle>Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta</scientifictitle>
    <utrn />
    <trialacronym>OI</trialacronym>
    <secondaryid>2014-000184-40</secondaryid>
    <secondaryid>20130173</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteogenesis Imperfecta</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Fractures</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Denosumab

Experimental: Denosumab - 


Treatment: drugs: Denosumab
All subjects will receive denosumab 1 mg/kg (up to a maximum of 60 mg) given subcutaneously every 6 months for 36 months.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline in lumbar spine BMD Z-score, as assessed by DXA, - Change in lumbar spine BMD Z-score, as assessed by DXA,</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in lumbar spine BMD Z-score, as assessed by DXA, at 6, 18, 24, - Change from baseline in lumbar spine BMD Z-score, as assessed by DXA, at 6, 18, 24, and 36 months</outcome>
      <timepoint>6.18,24,36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in proximal femur BMD Z-score, as assessed by DXA - Change in proximal femur BMD Z-score, as assessed by DXA, at 6, 12, 18, 24, and 36 months (in subjects 5 years of age and older)</outcome>
      <timepoint>6, 12, 18, 24, and 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of new and worsening fractures (X-ray confirmed long bone and vertebral - Incidence of new and worsening fractures (X-ray confirmed long bone and vertebral fractures) from pre-treatment to post-treatment at 12, 24, and 36 months</outcome>
      <timepoint>12, 24, and 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of improving vertebral fractures from pre-treatment to post-treatment - Incidence of improving vertebral fractures from pre-treatment to post-treatment at 12, 24, and 36 months (overall, among subjects with clinical fracture reduction, and among subjects with clinical fracture increase)</outcome>
      <timepoint>12, 24, and 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of pre-treatment compared with post-treatment vertebral and nonvertebral - Incidence of pre-treatment compared with post-treatment vertebral and nonvertebral fractures at 12, 24, and 36 months</outcome>
      <timepoint>12, 24, and 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Child Health Questionnaire (CHQ)-Parent Form (PF)-50 Physical Summary - Change in Child Health Questionnaire (CHQ)-Parent Form (PF)-50 Physical Summary score at 12, 24, and 36 months</outcome>
      <timepoint>12, 24, and 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in CHQ-PF-50 Psychological Summary score - Change in CHQ-PF-50 Psychological Summary score at 12, 24, and 36 months</outcome>
      <timepoint>12, 24, and 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Childhood Health Assessment Questionnaire (CHAQ) Disability Index score - Childhood Health Assessment Questionnaire (CHAQ) Disability Index score at 12, 24, and 36 months</outcome>
      <timepoint>12, 24, and 36 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Wong-Baker Faces Pain Rating Scale (WBFPRS) - Change in Wong-Baker Faces Pain Rating Scale (WBFPRS) at 12, 24, and 36 months</outcome>
      <timepoint>12, 24, and 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum concentration of denosumab - Serum concentration of denosumab at 1 and 10 days and 6, 12, 18, 24, 30, and 36 months in all subjects (additional serum denosumab pharmacokinetics [PK] samples to be collected at day 30 and month 3 in a PK/bone turnover markers (BTM) substudy of approximately 50 subjects).</outcome>
      <timepoint>1 and 10 days and 6, 12, 18, 24, 30, and</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Clinical diagnosis of OI defined as a clinical history consistent with type I-IV OI
        Clinical severity of OI as defined by 2 or more prevalent vertebral compression fractures;
        OR1 prevalent vertebral compression fracture and 1 or more nonvertebral fractures within
        the previous 2 years; OR 3 or more fractures within the previous 2 years.</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>17</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Inability or unwillingness to comply with the requirements for frequent calcium and
             phosphorus monitoring for 14 days after the first dose of denosumab (only applies to
             the first 5 subjects age 11 to17 enrolled in the study and the first 5 subjects of any
             age meeting the criteria for increased bone turnover

          -  Currently unhealed fracture or osteotomy as defined by orthopedic opinion

          -  Osteotomy within 5 months of screening

          -  Evidence of untreated oral cavities or oral infections

          -  Recent or planned invasive dental procedure

          -  Surgical tooth extraction which has not healed by screening

          -  History of an electrophoresis pattern inconsistent with type I to IV OI

          -  History of genetic testing results inconsistent with type I to IV OI

          -  Abnormalities of the following per central laboratory reference ranges at screening:
             Serum albumin corrected calcium &lt; lower limit of normal (LLN) Serum vitamin D &lt; 20
             ng/mL; re-screening for Vitamin D level &lt; 20 ng/mL will be allowed, after adequate
             supplementation

          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT) &gt; 1.5 x upper limit
             of normal (ULN)

               -  Total bilirubin (TBL) &gt; 1.5 x ULN (subjects with Gilbert syndrome are eligible)

               -  Serum phosphorus &lt; LLN

               -  Serum alkaline phosphatase &gt; 20% above the ULN or &gt; 20% below the LLN

               -  Estimated glomerular filtration rate (eGFR) &lt; 60 mL/min/1.73 m2 (calculated bythe
                  Schwartz equation at screening) Evidence of any of the following: Current
                  hyperthyroidism (unless well-controlled on stable antithyroid therapy)

               -  Current clinical hypothyroidism (unless well-controlled on stable thyroid
                  replacement therapy)

               -  History of hyperparathyroidism

               -  Current hypoparathyroidism

               -  Current, uncontrolled hypercalcemia (albumin-corrected serum Ca &gt;10% ULN)

               -  History of osteomalacia or rickets (chart review)

               -  Other bone diseases that affect bone metabolism (eg, osteoporosis pseudoglioma
                  syndrome, idiopathic juvenile osteoporosis, osteopetrosis, hypophosphatasia)

               -  History of autoimmune disease

               -  History of rare hereditary problems of fructose intolerance

               -  Positive blood screen for human immunodeficiency virus -1 or -2 antibody

               -  Positive blood screen for hepatitis B surface antigen or hepatitis C antibody

               -  Received other osteoporosis treatment or bone active treatment with the following
                  guidelines:

               -  Prior treatment with

               -  § denosumab

               -  § fluoride or strontium for bone disease

               -  § parathyroid hormone (PTH) or PTH derivatives within 12 months prior to
                  screening

               -  § zoledronic acid within 6 months prior to screening

               -  § oral bisphosphonates or intravenous bisphosphonates other than zoledronic acid
                  if the first dose of denosumab would be before their next scheduled
                  bisphosphonate dose would have been given

               -  Administration of systemic glucocorticoids (= 5.0 mg prednisone equivalents/day
                  for more than 10 days) within 3 months of screening.

               -  Topical and inhaled glucocorticoids will be allowed

               -  Administration of any of the following treatment within 3 months of screening:

               -  § Growth hormone (subjects on stable dose of growth hormone for at least 3 months
                  prior to screening will be allowed)

               -  Currently receiving treatment in another investigational drug study, or less than
                  30 days since ending treatment on another investigational drugstudy(s), or
                  current or planned participation in a clinical trial that would preclude
                  compliance with study requirements Other inclusion/exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>24/06/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/08/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Research Site - Westmead</hospital>
    <postcode>2145 - Westmead</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Varna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Pardubice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Plzen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 15</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Köln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Verona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cataluña</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Comunidad Valenciana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a prospective, multicenter, single-arm study in children 2 to 17 years of age with OI
      to evaluate efficacy and safety of denosumab.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02352753</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Amgen Call Center</name>
      <address />
      <phone>866-572-6436</phone>
      <fax />
      <email>medinfo@amgen.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>